SEC Form 4/A · accession 0000882104-16-000090
PDL BIOPHARMA, INC. · PDLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Christopher Lewis Stone
Officer — VP, Gen. Counsel & Secretary
Period of report
Apr 10, 2014
Accepted (ET)
Jan 28, 2016 · 6:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882104
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1,F2 | Apr 10, 2014 | A | 30,693 | $8.22 | A | 86,048 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved,based upon the following schedule: 50% on December 12, 2015; 16.66% on December 12, 2016; 16.66% on December 12, 2017; and 16.66% on December 12, 2018.
- F2The amount of securities beneficially owned following the transaction above is being amended to remove 21,315 shares which were incorrectly reported as being beneficially owned by Mr. Stone.